Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Our AI scores Cardiff Lexington Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Cardiff Lexington Corp is a small-cap company with a market capitalization of $110K. It ranks number 8 by market capitalization among the 8 Services-Offices & Clinics of Doctors of Medicine issuers in our coverage with a current forecast.
For CDIX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -41.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -30.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CDIX included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Offices & Clinics of Doctors of Medicine peers listed below that report each metric.
| Metric | CDIX | Rank |
|---|---|---|
| Market Cap | $110K | 8/8 |
| EPS | $-1.05 | – |
| Metric | CDIX | Rank |
|---|---|---|
| ROE | -561.3% | 5/5 |
| ROA | -32.1% | 6/7 |
| ROIC | -13.9% | 6/8 |
| Gross Margin | 61.0% | 5/6 |
| Operating Margin | -4.3% | 3/8 |
| Net Margin | -75.0% | 6/7 |
| EBT Margin | -42.5% | 7/8 |
| Metric | CDIX | Rank |
|---|---|---|
| Current Ratio | 0.91x | 4/8 |
| D/E Ratio | 15.44x | 1/6 |
| Financial Leverage | 17.48x | 1/6 |
| Interest Coverage | -109.8x | 7/8 |
| Working Capital | -$2M | 3/8 |
| Metric | CDIX | Rank |
|---|---|---|
| Operating Cash Flow | -$3M | 7/8 |
| Metric | CDIX | Rank |
|---|---|---|
| Payables Period | 108 days | 3/5 |
| Metric | CDIX | Rank |
|---|---|---|
| Operating Income | -$560K | 2/8 |
| Net Income | -$10M | 5/7 |
| SG&A Expense | $7M | 6/7 |
| Cost of Goods Sold | $5M | 6/6 |
| Metric | CDIX | Rank |
|---|---|---|
| Shares Outstanding | 12M | – |
| Total Current Assets | $24M | 79.2% of assets |
| Cash & Short-term Investments | $220K | 0.7% of assets |
| Accounts Receivable | $24M | 77.3% of assets |
| Total Liabilities | $27M | 88.3% of assets |
| Short-term Debt | $25M | 81.8% of assets |
Companies classified under the same SEC industry code as Cardiff Lexington Corp (Services-Offices & Clinics of Doctors of Medicine): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CDIX Cardiff Lexington Corp | $110K | |
| HIMS Hims & Hers Health, Inc. | $5.92B | |
| TDOC Teladoc Health, Inc. | $1.60B | |
| SBC Sbc Medical Group Holdings Inc | $518M | |
| STLN Starling Oncology, Inc. | $356M | |
| LFMD Lifemd, Inc. | $110M | |
| AIRS Airsculpt Technologies, Inc. | $38M | |
| HLYK Healthlynked Corp | $5M |
Cardiff Lexington Corp (CDIX) achieved positive adjusted EBITDA for the quarter, indicating operational profitability despite revenue challenges. The company upgraded to the OTC QX best market, ...
Full Year Revenue: $11.5 million, a 40% increase from $8.3 million in 2024. Fourth Quarter Revenue: $2.8 million, down from $3.1 million in the same quarter last year. Net Operating Margin: 9.5% for ...
Detailed price information for Cardiff Lexington Corp (CDIX) from The Globe and Mail including charting and trades.
Our AI scores Cardiff Lexington Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For CDIX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -41.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -30.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Cardiff Lexington Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
8 issuers in our coverage, CDIX included, share the SEC industry code Services-Offices & Clinics of Doctors of Medicine. The largest are: Hims & Hers Health, Inc. (HIMS), Teladoc Health, Inc. (TDOC), Sbc Medical Group Holdings Inc (SBC), Starling Oncology, Inc. (STLN), Lifemd, Inc. (LFMD), Airsculpt Technologies, Inc. (AIRS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
